ClinicalTrials.gg
CompletedNCT02414958Updated Jan 3, 2019Results posted

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

A Phase 3 interventional study of Empagliflozin and Empagliflozin in Diabetes Mellitus, Type 1, sponsored by Boehringer Ingelheim. Completed at 131 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 1.

Enrollment
2nd of 12
730 · median 49
Started
2015
with 1 other
Phase 3
4 of 12
1 open now
Registered
2nd of 12
by date
Lead sponsor
4 of 12
Boehringer Ingelheim

Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 2nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Randomisation to 3 treatments arms (equal assignment) following a screening period, an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week follow-up period.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient receiving insulin for the treatment of documented diagnosis of Type 1 Diabetes Mellitus (T1DM) for at least 1 year at the time of Visit 1
  • Fasting C-peptide value of \< 0.7 ng/mL (0.23 nmol/L) at Visit 2 measured by the central laboratory
  • Use of, and be willing, based on the Investigator's judgement, to continue throughout the duration of the trial, either:

    • Multiple Daily Injections (MDI) of insulin consisting of at least one basal insulin injection and at least three daily bolus injections OR
    • Continuous Subcutaneous Insulin Infusion (CSII) of any insulin type, with at least 5 months experience of using CSII prior to Visit 1
  • >/= 7.5% and \</= 10.0% at Visit 5 measured by the central laboratory
  • Age >/= 18 years at Visit 1

Additional inclusion criteria may apply

Exclusion criteria

Exclusion criteria:

  • History of Type 2 Diabetes Mellitus (T2DM), maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
  • Pancreas, pancreatic islet cells or renal transplant recipient
  • T1DM treatment with any other antihyperglycaemic drug (e.g. metformin, alpha-glucosidase inhibitors, Glucagon-like-peptide 1 (GLP-1) analogues, Sodium-Glucose Co-Transporter (SGLT-2) inhibitors, pramlintide, inhaled insulin, pre-mixed insulins etc.) except subcutaneous basal and bolus insulin within 3 months prior to Visit 1
  • Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that required hospitalisation or hypoglycaemia-related treatment by an emergency physician or paramedic within 3 months prior to Visit 1 and until randomisation
  • Occurence of Diabetic Ketoacidosis (DKA) within 3 months prior to Visit 1 and until randomisation

Additional exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
730 participants (actual)

Study arms

  • Experimental
    Empagliflozin low dose

    Empagliflozin tablets once daily

    Drug: Empagliflozin

  • Experimental
    Empagliflozin high dose

    Empagliflozin tablets once daily

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Placebo tablets matching empagliflozin once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26

    Change from baseline in glycated haemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.

    Time frame: Baseline to week 26

  2. Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )

    Change from baseline in glycated haemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.

    Time frame: Baseline to week 26

Secondary outcomes

  1. Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)

    This is a key secondary endpoint. Rate per patient-year of investigator-reported symptomatic hypoglycaemia adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycaemia AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycaemia events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate.

    Time frame: Week 5 to Week 26, Week 1 to Week 26

  2. Change From Baseline in Body Weight at Week 26

    Change from baseline in body weight is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

  3. Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26

    Change from baseline in the percentage of time spent in target glucose range of \>70 to ≤180 mg/dL (\>3.9 to ≤10.0 mmol/L) as determined by continuous glucose monitoring (CGM) is presented in week 23 to 26. Least squares mean is actually an adjusted event rate.

    Time frame: Week 23 to 26

  4. Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26

    Change from baseline in interstitial glucose variability based on the IQR as determined by CGM is presented for week 23 to 26. Least squares mean is actually an adjusted event rate.

    Time frame: Week 23 to 26

  5. Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26

    Change from baseline in TDID is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

  6. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26

    Change from baseline in SBP and DBP is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.

    Time frame: Baseline to week 26

07

Results

Posted Nov 20, 2018

Participant flow

Randomised, double-blind, placebo-controlled, parallel group, 52-week trial comparing 2 oral once daily doses (10 mg and 25 mg) of empagliflozin with placebo in patients with type 1 diabetes mellitus (T1DM), each as adjunctive to optimised insulin therapy.

Participant flow — Overall Study
MilestonePlacebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Started243243244
Completed211223230
Not completed322014
Withdrew: Adverse event663
Withdrew: Protocol violation1031
Withdrew: Lost to follow-up740
Withdrew: Withdrawal by subject535
Withdrew: Other than specified445

Outcome measures

PrimaryChange From Baseline in Glycated Haemoglobin (HbA1c) at Week 26

Change from baseline in glycated haemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Percentage (%)
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26
Percentage (%)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 260.09 ± 0.04-0.44 ± 0.04-0.44 ± 0.04
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Mixed effect Model Repeated Measures · p = <0.0001 · Mean difference (final values): -0.54 · 97.5% CI -0.66 to -0.41Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · MMRM · p = <0.0001 · Mean difference (final values): -0.53 · 97.5% CI -0.66 to -0.41Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean
PrimaryChange From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )

Change from baseline in glycated haemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Percentage (%)
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )
Percentage (%)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )0.09 ± 0.04-0.43 ± 0.04-0.42 ± 0.04
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · MMRM · p = <0.0001 · Mean difference (final values): -0.53 · 97.5% CI -0.65 to -0.40Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · MMRM · p = <0.0001 · Mean difference (final values): -0.51 · 97.5% CI -0.64 to -0.39Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
SecondaryRate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)

This is a key secondary endpoint. Rate per patient-year of investigator-reported symptomatic hypoglycaemia adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycaemia AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycaemia events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate.

Time frame:
Week 5 to Week 26, Week 1 to Week 26
Reported as:
Least squares mean · Event per patient year
Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
Event per patient yearPlacebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Week 5 to 268.92 (7.15 to 11.14)6.64 (5.32 to 8.28)6.48 (5.18 to 8.12)
Week 1 to 269.13 (7.36 to 11.34)7.07 (5.70 to 8.76)7.15 (5.75 to 8.88)
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Negative binomial model · p = 0.0623 · Adjusted rate ratio (%): 0.744 · 97.75% CI 0.518 to 1.069Empagliflozin 10 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · Negative binomial model · p = 0.0480 · Adjusted rate ratio (%): 0.726 · 97.75% CI 0.502 to 1.501Empagliflozin 25 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · Negative binomial model · p = 0.0972 (This is a nominal p-value.) · Adjusted rate ratio (%): 0.774 · 95% CI 0.572 to 1.048Empagliflozin 10 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · MMRM · p = 0.1180 (Negative binomial model) · Adjusted rate ratio (%): 0.782 · 97.75% CI 0.575 to 1.064Empagliflozin 25 milligram (mg) adjusted rate/Placebo matching Empagliflozin adjusted rate.
SecondaryChange From Baseline in Body Weight at Week 26

Change from baseline in body weight is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline in Body Weight at Week 26
Kilogram (kg)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Body Weight at Week 26-0.10 ± 0.21-2.79 ± 0.20-3.37 ± 0.20
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · MMRM · p = <0.0001 · Mean difference (final values): -2.69 · 99.75% CI -3.57 to -1.80Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · MMRM · p = <0.0001 · Mean difference (final values): -3.27 · 99.75% CI -4.15 to -2.39Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
SecondaryChange From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26

Change from baseline in the percentage of time spent in target glucose range of \>70 to ≤180 mg/dL (\>3.9 to ≤10.0 mmol/L) as determined by continuous glucose monitoring (CGM) is presented in week 23 to 26. Least squares mean is actually an adjusted event rate.

Time frame:
Week 23 to 26
Reported as:
Least squares mean · Percentage of time
Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26
Percentage of timePlacebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26-1.13 ± 0.7210.73 ± 0.7111.74 ± 0.70
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · ANCOVA · p = <0.0001 · Mean difference (final values): 11.86 · 99.75% CI 8.78 to 14.93Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · ANCOVA · p = <0.0001 · Mean difference (final values): 12.87 · 99.75% CI 9.81 to 15.93Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean
SecondaryChange From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26

Change from baseline in interstitial glucose variability based on the IQR as determined by CGM is presented for week 23 to 26. Least squares mean is actually an adjusted event rate.

Time frame:
Week 23 to 26
Reported as:
Least squares mean · milligrams (mg)/ deciliter (dL)
Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26
milligrams (mg)/ deciliter (dL)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 261.62 ± 1.21-15.30 ± 1.18-17.41 ± 1.16
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -16.92 · 99.75% CI -22.04 to -11.81Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -19.04 · 99.75% CI -24.13 to -13.95Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
SecondaryChange From Baseline in Total Daily Insulin Dose (TDID) at Week 26

Change from baseline in TDID is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Unit/kilogram (U/kg)
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
Unit/kilogram (U/kg)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26-0.010 ± 0.007-0.102 ± 0.007-0.100 ± 0.007
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · MMRM · p = <0.0001 · Mean difference (final values): -0.092 · 99.75% CI -0.121 to -0.063Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · MMRM · p = <0.0001 · Mean difference (final values): -0.090 · 99.75% CI -0.119 to -0.062Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26

Change from baseline in SBP and DBP is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.

Time frame:
Baseline to week 26
Reported as:
Least squares mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
Millimeters of mercury (mmHg)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
SBP-0.8 ± 0.7-2.9 ± 0.7-4.5 ± 0.7
DBP-0.3 ± 0.5-1.6 ± 0.5-2.6 ± 0.5
Statistical analysis
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · MMRM · p = 0.0397 · Mean difference (final values): -2.1 · 99.75% CI -5.2 to 1.0Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · MMRM · p = 0.0003 · Mean difference (final values): -3.7 · 99.75% CI -6.8 to -0.6Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 10 mg · MMRM · p = 0.0457 (Nominal p-value) · Mean difference (final values): -1.3 · 99.75% CI -2.7 to 0.0Mean Difference= Empagliflozin 10 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.
  • Placebo Matching Empagliflozin vs Empagliflozin 25 mg · MMRM · p = 0.0006 · Mean difference (final values): -2.3 · 99.75% CI -4.3 to -0.3Mean Difference= Empagliflozin 25 milligram (mg) adjusted mean - Placebo matching Empagliflozin adjusted mean.

Adverse events

Collected over From the first dose of trial medication until 7 days after last in-take of trial medication, up to 422 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Matching Empagliflozin0/243 (0%)28/243 (11.5%)197/243 (81.1%)
Empagliflozin 10 mg0/243 (0%)43/243 (17.7%)197/243 (81.1%)
Empagliflozin 25 mg0/244 (0%)26/244 (10.7%)195/244 (79.9%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventPlacebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
Diabetic ketoacidosisMetabolism and nutrition disorders4/24312/2438/244
HypoglycaemiaMetabolism and nutrition disorders6/2439/2433/244
KetoacidosisMetabolism and nutrition disorders2/2434/2432/244
FallInjury, poisoning and procedural complications0/2432/2430/244
HyperglycaemiaMetabolism and nutrition disorders2/2431/2431/244
DeafnessEar and labyrinth disorders0/2430/2432/244
PneumoniaInfections and infestations0/2430/2432/244
Acute myocardial infarctionCardiac disorders1/2430/2430/244
Cardiac failure congestiveCardiac disorders0/2431/2430/244
Coronary artery stenosisCardiac disorders0/2431/2430/244
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mg
HypoglycaemiaMetabolism and nutrition disorders152/243154/243147/244
NasopharyngitisInfections and infestations41/24352/24343/244
Urinary tract infectionInfections and infestations29/24337/24320/244
Upper respiratory tract infectionInfections and infestations25/24315/24327/244
InfluenzaInfections and infestations11/24320/24312/244
Blood ketone body increasedInvestigations10/24318/24320/244
VomitingGastrointestinal disorders12/24319/24312/244
NauseaGastrointestinal disorders14/24312/24314/244
SinusitisInfections and infestations13/24314/2439/244
Vulvovaginal mycotic infectionInfections and infestations2/2439/24314/244

Baseline characteristics

Randomised set (RS): All patients from the screened set (SCR) who were randomised to trial medication regardless of whether any trial medication was taken.

Age, Continuous
Age, Continuous(Years)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean44.2 ± 13.645.7 ± 12.545.3 ± 14.045.0 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Female133125131389
Male110118113341
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Hispanic or Latino74617
Not Hispanic or Latino236239238713
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Matching EmpagliflozinEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
American Indian or Alaska Native0000
Asian761023
Native Hawaiian or Other Pacific Islander0101
Black or African American76417
White227230230687
More than one race2002
Unknown or Not Reported0000
08

Study locations

131 sites
  • AMCR Institute, Inc.
    Escondido, California 92025, United States
  • Diabetes/Lipid Management and Research Center
    Huntington Beach, California 92648, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Mills-Peninsula Health Services
    San Mateo, California 94401, United States
  • Metabolic Institute of America
    Tarzana, California 91356, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Creekside Endocrine Associates, PC
    Denver, Colorado 80246, United States
  • The Center for Diabetes and Endocrine Care
    Fort Lauderdale, Florida 33312, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32204, United States
  • Baptist Diabetes Associates, PA
    Miami, Florida 33156, United States
  • Physicians Research Associates, LLC
    Lawrenceville, Georgia 30046, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Northwest Endo Diabetes Research, LLC
    Arlington Heights, Illinois 60005, United States
  • Midwest Endocrinology
    Crystal Lake, Illinois 60012, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Diabetes anddocrine Associates, PC
    Omaha, Nebraska 68114, United States
  • Desert Endocrinology Clinical Research Center
    Henderson, Nevada 89052, United States
  • Palm Research Center
    Las Vegas, Nevada 89148, United States
  • Southern New Hampshire Diabetes and Endocrinology
    Nashua, New Hampshire 03063, United States
  • Albany Medical Center / Albany Medical College
    Albany, New York 12206, United States
  • University Physicians Group Research Division
    Staten Island, New York 10301, United States
  • Diabetes and Endocrinology Consultants, PC
    Morehead City, North Carolina 28557, United States
  • The Carl and Edyth Lindner Center for Research & Education at The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Diabetes and Obesity Clinical Trials Center
    Nashville, Tennessee 37212, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Office of Dr. Michelle Zaniewski-Singh
    Houston, Texas 77090, United States
  • Texas Diabetes and Endocrinology
    Round Rock, Texas 78681, United States
  • Bateman Horne Center
    Salt Lake City, Utah 84102, United States
  • Advanced Research Institute
    South Ogden, Utah 84405, United States
  • Larry D Stonesifer, MD Inc., PS
    Federal Way, Washington 98003, United States
  • Rainier Clinical Research Center, Inc
    Renton, Washington 98057, United States
  • The Polyclinic
    Seattle, Washington 98104, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Coffs Endocrine & Diabetes Services
    Coffs Harbour, New South Wales 2450, Australia
  • AIM Centre
    Merewether, New South Wales 2291, Australia
  • Royal Brisbane & Women's Hospital-Endocrinology
    Herston, Queensland 4006, Australia
  • VIVIT Instit.am LKH Feldkirch,Abt.f.Innere Med.u.Kardiologie
    Feldkirch, 6807, Austria
  • LKH Steyr, Kardiologie
    Steyr, 4400, Austria
  • KH Rudolfstiftung, 1. Med. Abt., Wien
    Wien, 1030, Austria
  • Hospital Hietzing
    Wien, 1130, Austria
  • Arlon - HOSP Sud Luxembourg - Vivalia
    Arlon, 6700, Belgium
  • Bonheiden - HOSP Imelda
    Bonheiden, 2820, Belgium
  • Brussels - UNIV UZ Brussel
    Brussel, 1090, Belgium
  • ULB Hopital Erasme
    Bruxelles, 1070, Belgium
  • Edegem - UNIV UZ Antwerpen
    Edegem, 2650, Belgium
  • UNIV UZ Gent
    Gent, 9000, Belgium
  • La Louvière - UNIV CHU Tivoli
    La Louvière, 7100, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Liège - HOSP CHR de la Citadelle
    Liège, 4000, Belgium
  • Merksem - HOSP ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • LMC Endocrinology Centres (Calgary) Ltd.
    Calgary, Alberta T2H 2G4, Canada
  • The Bailey Clinic
    Red Deer, Alberta T4N 6V7, Canada
  • Royal Jubilee Hospital
    Victoria, British Columbia V8R 1J8, Canada
  • Health Sciences Centre Winnipeg
    Winnipeg, Manitoba R3E 3P4, Canada
  • CHUM - Pavillon R
    Montreal, Migration Data Quebec, Canada
  • Capital District Health Auth.
    Halifax, Nova Scotia B3H 1V7, Canada
  • Kingston General Hospital
    Kingston, Ontario K7L 2V7, Canada
  • LMC Thornhill/Vaughan
    Thornhill, Ontario L4J 8L7, Canada
  • Mount Sinai Hospital
    Toronto, Ontario M5T 3L9, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H3A 1A1, Canada
  • General Univ.hosp.in Prague (VFN), Diabetes ambulance
    Praha 2, 128 08, Czechia
  • Diabetology and Internal Practice Dr. Vladimir Lelek
    Slany, 274 01, Czechia
  • Masaryk Hospital, Internal Department
    Usti nad Labem, 401 13, Czechia
  • Aalborg Sygehus Syd
    Aalborg, 9100, Denmark
  • Aarhus Universitets Hospital
    Aarhus C, 8000, Denmark
  • Steno Diabetes Center Copenhagen
    Gentofte, 2820, Denmark
  • Nordsjællands Hospital - Hillerød
    Hillerød, 3400, Denmark
  • Køge Sygehus
    Køge, 4600, Denmark
  • IteLasaretti
    Kuopio, FI-70100, Finland
  • Terveystalo Oulu, Diapolis
    Oulu, FI-90100, Finland
  • TYKS
    Turku, FI-20520, Finland
  • HOP Côte de Nacre
    Caen, 14033, France
  • HOP Saint-Louis
    La Rochelle Cedex 1, 17000, France
  • HOP de Narbonne, diabéto endo, Narbonne
    Narbonne, 11100, France
  • HOP Robert Debré
    Reims, 51092, France
  • HOP de Brabois
    Vandoeuvre-lès-Nancy, 54511, France
  • HOP les Portes du Sud, Diabéto, Vénissieux
    Vénissieux, 69200, France
  • Studienzentrum Aschaffenburg
    Aschaffenburg, 63739, Germany
  • Gemeinschaftspraxis, Asslar
    Asslar, 35614, Germany
  • ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH
    Berlin, 10115, Germany
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Praxis Dr. Kosch, Pirna
    Pirna, 01796, Germany
  • Allgemeinmedizinische und Diabetologische Schwerpunktpraxis
    Rehlingen-Siersburg, 66780, Germany
  • Praxis Dr. Hirschhäuser
    Saarbrücken, 66121, Germany
  • Praxis Dr. Segner, St. Ingbert
    Saint Ingbert/Oberwürzbach, 66386, Germany
  • Ambulanzzentrum Schweinfurt
    Schweinfurt, 97421, Germany
  • Noordwest Ziekenhuisgroep
    Alkmaar, 1815 JD, Netherlands
  • Academisch Medisch Centrum (AMC)
    Amsterdam, 1105 AZ, Netherlands
  • Rijnstate Hospital
    Arnhem, 6815 AD, Netherlands
  • Martini Ziekenhuis
    Groningen, 9728 NT, Netherlands
  • Bethesda Ziekenhuis Hoogeveen
    Hoogeveen, 7909 AA, Netherlands
  • Sint Franciscus Gasthuis
    Rotterdam, 3045 PM, Netherlands
  • Albert Schweitzer Ziekenhuis, Zwijndrecht
    Zwijndrecht, 3331 LZ, Netherlands
  • Sykehuset Innlandet HF, Avd. Hamar
    Hamar, N-2318, Norway
  • Akershus Universitetssykehus HF
    Lørenskog, N-1478, Norway
  • Oslo Universitetssykehus HF, Aker Sykehus
    Oslo, N-0424, Norway
  • Helse Møre og Romsdal HF, Ålesund sjukehus
    Ålesund, N-6026, Norway
  • Med Univ Bialystok Clin Dep Endocrinol, Diabetol & Int Dis
    Bialystok, 15-276, Poland

Showing the first 100 of 131 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4. PubMed 30287422 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Apr 2017, 21 months.

Results were first posted in Nov 2018, 1 year 7 months after primary completion. A results delay was requested in Apr 2018.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 21 months is above that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2015
First posted
Apr 13, 2015
StartActual
Jun 30, 2015
Primary completionActual
Apr 20, 2017
CompletionActual
Oct 23, 2017
Results delay requested
Apr 10, 2018
Results first posted
Nov 20, 2018
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02414958
Responsible party
Sponsor
First posted
Apr 13, 2015
Start date
Jun 30, 2015
Primary completion
Apr 20, 2017
Completion
Oct 23, 2017
Results posted
Nov 20, 2018
Last update
Jan 3, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion